Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?

Tonix readies for pivotal Fibromyalgia program

Thursday 21 March 2013

 

From business website Seeking Alpha:

 

Tonix PharmaceuticalsTonix Readies For Pivotal Fibromyalgia Program

Jason Napodano
Mar 13 2013, 05:35 | about: TNXP.OB

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

In February 2013, Tonix Pharmaceuticals (TNXP.OB) management met face-to-face with the U.S. FDA to discuss the design of the clinical program for TNX-102SL, the company's low-dose sublingual formulation of cyclobenzaprine for the treatment of fibromyalgia syndrome. Management believes the results of the meeting were positive, and that a clear path to approval has been outlined. We discuss the proposed plan below:

...Phase IIb…

During the third quarter 2013, Tonix plans to initiate a prospective Phase IIb study to assess the safety and efficacy of TNX-102SL in patients with fibromyalgia. The double-blind / placebo-controlled study will seek to enroll 100-200 patients with fibromyalgia at 10 centers all around the U.S. Patients will be randomized to receive either TNX-102SL (2.8mg) or placebo at bedtime nightly for 12 weeks. The primary endpoint will be pain severity at week 12 as assessed by the Numeric Rating Scale (NRS).

We note this endpoint is similar to that utilized by Pfizer (PFE) and Eli Lilly (LLY) to gain approval for Lyrica and Cymbalta, respectively, for the treatment of fibromyalgia syndrome. Placebo response will be a key issue to watch. Tonix plans to include a 1-2 week wash-out period prior to randomization. We note the Pfizer Phase III study with Lyrica showed a placebo response rate of nearly 50%.

The company will also collect information on secondary endpoints, including NRS scores at other time points during the 12 week study, the Fibromyalgia Impact Questionnaire (FIQ), and the Patient Global Impression of Change (PGIC). We suspect that the trial will take about 12 months to enroll and report top-line data, at an all-in cost of around $4-5 million.

…Phase III…

If the proposed Phase IIb trial noted above is successful, Tonix plans to proceed into confirmatory Phase III registration study. We suspect that the Phase III study will follow a similar design to the proposed Phase IIb study, only slightly larger at 300 patients, and incorporate the same change in NRS from baseline to week 12 primary endpoint, and NRS, FIQ, and PGIC secondary endpoints. Assuming this study initiates late 2014, we believe data can be reported by the middle of 2016, allowing for a U.S. NDA filing in early 2017.

…Pharmacokinetic Reference Study…

Besides the two registration efficacy studies noted above, Tonix plans to conduct a multi-dose pharmacokinetic study with TNX-102SL in comparison to generic cyclobenzaprine in a multiple-day dosing (once daily) study. In the study, peak and trough blood levels of cyclobenzaprine will be measured in subjects that receive either TNX-102SL or generic cyclobenzaprine immediate release for 4-5 consecutive days. The goal of the study is to show a bridge between 2.8mg TNX-102SL and generic 5mg cyclobenzaprine that will allow for use of the generic tablet as a reference product in the planned 505(b)(2) NDA submission.

(Please note: The above was Page 1 of a 2-page article. Page 2 is available by subscription only.)

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page